GleamWall
中文EN

NIKA NIKA PHARMACEUTICALS, INC

Pharmaceutical Preparations · OTC · SEC CIK 1145604 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-60.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-574.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets6,574.0%
Debt / equity—
Current ratio0.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-85.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue—$0
SG&A expense$53,026$35,174
Operating income-$76,398-$95,792
Pretax income-$76,398-$95,792
Net income-$76,398-$95,792
EPS (basic)0.000.00
EPS (diluted)0.000.00
Weighted avg. shares (diluted)1.05B1.02B
Balance sheet
Cash & equivalents$1,889$2,083
Current assets$20,996$17,934
Total assets$20,996$17,934
Current liabilities$318,624$239,164
Short-term debt$318,624$239,164
Total liabilities$318,624$239,164
Shareholders' equity-$297,628-$221,231
Shares outstanding1.05B1.05B
Cash flow statement
Operating cash flow-$79,654-$154,932
Financing cash flow$79,460$137,419

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.